Related by context. All words. (Click for frequent words.) 78 Board DSMB 72 unblinded 68 Committee IDMC 66 DSMB recommended 65 Phase 2b study 65 APPRAISE 64 SYMMETRY trial 64 LibiGel Phase III 63 viral kinetic 63 phase IIb clinical 63 phase IIb 63 aflibercept 62 ENDEAVOR IV 62 Phase 2a trial 62 dose escalation 62 Phase Ib clinical 62 Phase #b/#a 62 placebo controlled studies 61 oral ridaforolimus 61 pharmacokinetic PK 61 clinical trial 61 phase IIa 61 unblind 61 MERLIN TIMI 61 Phase Ib 61 Phase 1b trial 60 MADIT II 60 BCIRG 60 Phase IIa trial 60 SUCCEED trial 60 clinical pharmacology studies 60 placebo controlled clinical 60 CUSTOM III 60 Phase III clinical 60 multicenter Phase II 60 abatacept 60 phase Ib 60 Phase 1b 60 EMPHASIS HF trial 60 Phase IIB 60 randomized Phase III 60 phase IIb trial 59 muraglitazar 59 dosing cohorts 59 placebo controlled Phase III 59 NATRECOR R 59 Phase Ib study 59 randomized controlled clinical trials 59 Phase III pivotal 59 LUX Lung 59 pharmacokinetic PK study 59 CHAMPION PLATFORM 59 Phase 2a 59 Phase III metastatic melanoma 59 cangrelor 59 Phase IIb 59 unblinding 59 randomized Phase IIb 59 EchoCRT 59 CALGB # [002] 59 CHAMPION PCI 59 FDA Advisory Panel 59 randomized Phase 2b 59 tesmilifene 59 phase IIb study 59 phase IIIb 59 Phase Ib II 59 nab paclitaxel 59 PIX# [002] 59 HCV SPRINT 59 ataluren 59 FDA Oncologic Drugs 59 multicenter Phase 59 vicriviroc 58 rALLy trial 58 Phase IIIb clinical 58 placebo controlled clinical trials 58 APTIVUS 58 Phase Ia 58 RE LY ® 58 HORIZONS AMI trial 58 placebo controlled Phase 58 Ocrelizumab 58 STRIDE PD 58 RSD# oral 58 Gynecologic Oncology Group 58 AIM HIGH 58 PEARL SC 58 Phase 1b clinical 58 confirmatory clinical 58 ADVANCE PD 58 Phase IIb trial 58 AVADO 58 NSABP 58 IMPROVE IT 58 ILLUMINATE 58 ADAGIO study 58 APEX AMI trial 58 Dacogen injection 58 Dose escalation 58 ATACAND 58 forodesine 58 blinded randomized 58 MEND CABG II 58 Phase IIb trials 58 ACRIN 58 PROPEL trial 58 MEND CABG 58 AVERROES 58 figitumumab 58 CONSERV 58 daclizumab 58 MADIT CRT 57 multiple ascending dose 57 Cethromycin 57 brivaracetam 57 prospective randomized placebo 57 ONTARGET 57 dose escalation Phase 57 AZILECT R 57 double blinded placebo 57 efficacy endpoints 57 ocrelizumab 57 placebo controlled trials 57 prospectively defined 57 secondary efficacy endpoints 57 vandetanib 57 MIRCERA 57 TAXUS IV 57 Phase 1a 57 deforolimus 57 RE LY 57 CRMD# 57 Phase 2b trial 57 Maximum Tolerated Dose 57 SIMPADICO 57 Phase IIb clinical 57 DAPT 57 ENRICH trial 57 Elocalcitol 57 PFO migraine 57 octreotide implant 57 REVLIMID lenalidomide 57 HCV RESPOND 2 57 dose escalation phase 57 dose cohort 57 FAME Study 57 sNDA submission 57 alvimopan 57 dose escalation trial 57 mcg dose 57 iPrEx 57 Canvaxin 57 Phase 2b clinical 57 glufosfamide 57 PROMACTA 57 ECASS 57 phase IIa clinical 57 BARI 2D 57 Xelox 57 prospective multicenter 57 eprotirome 57 Sibutramine Cardiovascular Outcomes 57 PRIMO CABG 57 arzoxifene 57 Pivotal Trial 57 senicapoc 57 pertuzumab 56 HGS# 56 sunitinib 56 CARE HF 56 Phase III trials 56 Oncologic Drugs Advisory 56 Phase IIa clinical 56 nonrandomized 56 EVEREST II 56 fosbretabulin 56 Phase IIb III 56 Phase IIa trials 56 PREZISTA r 56 RE LY trial 56 bicifadine 56 Vernakalant 56 PRIMO CABG2 56 Fablyn 56 posaconazole 56 Phase III HEAT 56 phase 2a 56 BRIM2 56 prospective randomized multicenter 56 ruboxistaurin 56 SABCS 56 APEX PD 56 pharmacodynamics PD 56 primary endpoint 56 pegloticase 56 HPTN 56 dosing cohort 56 CLIRS 56 ALLHAT 56 Multaq R 56 Asentar 56 Phase #/#a 56 Phase 2b kidney transplant 56 randomized clinical trials 56 Phase IIb clinical trials 56 Hydroxyurea 56 Aurexis 56 LUMINATE 56 multicenter trials 56 multicenter phase 56 Phase 2a clinical 56 Bicifadine 56 Aflibercept 56 PROTECT II 56 placebo controlled 56 PERSEUS 56 randomized trials 56 NSABP C 56 subgroup analyzes 56 ENDEAVOR III 56 APTIVUS r 56 ToGA 56 PRECISE trial 56 ACTEMRA 56 DASISION 56 primary efficacy endpoints 56 registrational trial 56 dosage regimens 56 ASA# 55 Thorough QT 55 trastuzumab emtansine T DM1 55 NO# [002] 55 ENDEAVOR II 55 PXD# 55 ABSORB trial 55 postmarketing surveillance 55 Plicera 55 Prostate AdenoCarcinoma Treatment 55 prespecified 55 PRE SURGE 55 GAMMAGARD 55 noninferiority 55 ASCEND HF 55 GVAX 55 BioNumerik 55 OPT CHF 55 Onrigin 55 CAPRISA 55 peg IFN 55 dirucotide 55 mapatumumab 55 multicentre 55 EDEMA3 55 Phase III psoriasis 55 SPIRIT FIRST 55 active comparator 55 PRECISE Trial 55 PARTNER Trial 55 BRIM3 55 Phase 1a clinical 55 TELCYTA 55 midstage clinical 55 NATRECOR ® 55 ongoing Phase IIIb 55 Torisel 55 MAGE A3 ASCI 55 Phase IIa 55 mg dose 55 efficacy tolerability 55 confirmatory Phase III 55 ganetespib 55 tolerability 55 REALITY Trial 55 elotuzumab 55 Phase #b/#a trial 55 randomized blinded 55 TOLAMBA 55 Ranolazine 55 valopicitabine 55 multicenter clinical 55 GLP toxicology studies 55 PRISTIQ 55 ACTIVE W 55 TASKi2 55 Prostate Lung Colorectal 55 SPIRIT IV 55 iclaprim 55 Xinlay 55 multicenter placebo controlled 55 PROSTVAC ® 55 HeFT 55 ongoing Phase 1b 55 SPIRIVA HandiHaler 55 randomized controlled Phase 55 CALGB 55 Prosaptide 55 riociguat 55 budesonide foam 55 SCD HeFT 55 pivotal Phase III 55 NEBIDO 55 BLA submission 55 Rasilez Tekturna 55 VITAL Trial 55 Phase III 55 randomized Phase 55 enzastaurin 55 AVOREN 55 PREVENT IV 55 maximally tolerated dose 55 romiplostim 55 PRADAXA 55 Candesartan 55 ARCOXIA 55 Phase 2b 55 neratinib 55 VIRAMUNE XR 55 FOLOTYN ® 55 apricitabine 55 CIMZIA TM 55 NP2 Enkephalin 55 multicenter randomized double 55 Glufosfamide 54 motesanib 54 ACTEMRA TM 54 QLT# 54 multicenter randomized placebo controlled 54 efficacy endpoint 54 Phase IIIb study 54 EMPHASIS HF 54 Metabolic Drugs Advisory 54 TACI Ig 54 AZOR 54 randomized multicenter 54 CoFactor 54 Viprinex 54 lorcaserin Phase 54 clazosentan 54 dose dose escalation 54 clevidipine 54 CAMMS# 54 motavizumab 54 μg dose 54 Prostate Cancer Prevention 54 multicenter randomized controlled 54 HuMax EGFr 54 CA4P 54 placebo controlled randomized 54 INCB# [001] 54 interferon gamma 1b 54 phase Ib clinical 54 eniluracil 54 EURIDIS 54 pharmacodynamic effects 54 ozarelix 54 tocilizumab 54 teriflunomide 54 Ophena 54 denufosol 54 Revlimid lenalidomide 54 ISENTRESS 54 MIST II 54 PFO closure 54 Kynapid 54 prospective randomized controlled 54 CR# vcMMAE 54 vismodegib 54 tolerated dose MTD 54 Phase #b/#a clinical 54 ANCHOR trial 54 HF ACTION 54 blind randomized placebo 54 GetGoal Phase III 54 Phase III randomized 54 tolerability profiles 54 serum phosphorous 54 bevacizumab Avastin 54 nonclinical studies 54 ponatinib 54 axitinib 54 peginesatide 54 Phase III multicenter 54 XL# SAR# 54 PEG SN# 54 ezogabine 54 PLCO 54 ORMD 54 canakinumab 54 GRAVITAS trial 54 REG1 54 rivaroxaban 54 elesclomol 54 randomized controlled 54 ZYBRESTAT 54 IMC A# 54 GOUT 54 velafermin belinostat 54 velafermin 54 APPROVe 54 Pimavanserin 54 bevirimat Study 54 mg kg dose 54 Prestara 54 ASSERT trial 54 nesiritide 54 ELND# 54 Corlux 54 multicentre randomized 54 VADT 54 Opexa 54 dose regimens 54 darusentan 54 Tavocept 54 raltegravir 54 ZOLINZA 54 lintuzumab 54 Amigal 54 ExTRACT TIMI 54 Golimumab 54 zalutumumab 54 Hyphanox 54 virologic failure 54 rindopepimut 54 FOLPI 54 confirmatory Phase 3 54 clinical trials 54 SIMPADICO trial 54 PROSTVAC TM 54 alvespimycin 54 registrational 54 randomized controlled clinical 54 Phase III placebo controlled 53 randomized clinical 53 elagolix 53 MAA submission 53 IMPROVE HF 53 QNEXA 53 Efficacy Results 53 Ushercell 53 dronedarone 53 zotarolimus eluting stent 53 albinterferon alfa 2b 53 non inferiority 53 prospective randomized 53 BLA filing 53 Amrubicin 53 SAR# [004] 53 LEXIVA r 53 Pivotal Clinical Trial 53 afatinib 53 Sulonex 53 TRO# 53 pomalidomide 53 recurrent glioblastoma multiforme 53 AIDAC 53 Tanespimycin 53 pharmacokinetics PK 53 AZILECT ® 53 Phase IIIb 53 Triolex 53 Pharmacokinetic 53 RE SURGE 53 vidofludimus 53 ELCAP 53 substudy 53 dimebon 53 Tolvaptan 53 single ascending dose 53 Vectibix 53 Prospective Randomized 53 EMPOWER ™ 53 null responder HCV 53 Dr. Yatscoff 53 NLX P# 53 Zerenex 53 PSN# [002] 53 sapacitabine 53 SinuNase 53 dosing 53 Heart Failure Trial 53 preclinical pharmacokinetic 53 HGS ETR1 53 Viramidine 53 RIO Lipids 53 PRECiSE 53 COMFORT II 53 randomized placebo controlled 53 Aptivus ® 53 ACUITY trial 53 Platelet Inhibition 53 BENICAR HCT 53 tipranavir 53 FDA Endocrinologic 53 vernakalant oral 53 tolvaptan 53 glatiramer acetate 53 PLCO trial 53 pivotal Phase 53 pramlintide 53 Cimzia TM 53 Cloretazine 53 MDV# 53 thorough QT 53 AIR CF2 53 Study GL# 53 LibiGel ® 53 GALNS 53 Potiga 53 mg/m2 cohort 53 Dr. McHutchison 53 ascending doses 53 Heplisav 53 Targretin 53 timepoint 53 bazedoxifene 53 dose cohorts 53 peginterferon 53 Zenvia Phase III 53 CLIRS trial 53 antithrombotic therapy 53 Medidur TM FA 53 COU AA 53 Carotid Revascularization Endarterectomy vs. 53 ascending dose 53 prospective multicentre 53 dose escalation study 53 pivotal bioequivalence 53 HyQ 53 oral deforolimus 53 ritonavir boosted 53 NVA# 53 Pafuramidine 53 treatment naive genotype 53 clinical endpoints 53 vernakalant 53 blinded randomized placebo controlled 53 primary endpoints 53 AIR CF1 53 ancrod 53 efficacy 53 Ozarelix 53 TORISEL 53 oral anticoagulant 53 GSK# [001] 53 Allovectin 7 ® 53 rNAPc2 53 preclinical efficacy 53 obatoclax 53 CRLX# 53 pegylated interferon alfa 2b 53 paliperidone palmitate 53 TMC# C# 53 anakinra 53 ISIS # 53 masked placebo controlled 53 Phase III Clinical Trials 53 ULORIC 53 GAMMAGARD LIQUID 53 Phase III Pivotal 53 Phase IIa clinical trials 53 Pivotal Phase 53 romidepsin 53 Tocosol Paclitaxel 53 NOXAFIL 53 aleglitazar 53 cortical stimulation 53 Virulizin ® 53 virologic 53 Adalimumab 53 Azixa 53 Augment Injectable 53 multicenter 53 ALTU 53 tolerability profile 53 Phenoptin 53 UPLYSO 53 Phase III Clinical Trial 53 baminercept 53 dose titration 53 R# #mg BID 53 Phase 2b Clinical Trial 52 dose escalation clinical 52 CCR5 antagonist 52 RIO Diabetes 52 Pivotal Phase III 52 PRoFESS 52 satraplatin Phase 52 PRECISE 52 ACCORD Lipid 52 PS# [001] 52 oral rivaroxaban 52 randomized discontinuation trial 52 Phase Ib clinical trials 52 Mylotarg 52 rFVIIa 52 composite endpoint 52 peg interferon 52 Tarceva TM 52 TRITON TIMI 52 ARDIS 52 Phase III confirmatory 52 Phase III clinical trials 52 oral FTY# 52 adecatumumab 52 prospective observational 52 Diabetic Macular Edema 52 HuMax CD4 52 Maximum Tolerated Dose MTD 52 ISTODAX 52 RhuDex 52 TEMSO 52 MADIT CRT trial 52 Fibrillex TM 52 Aggressive Reduction 52 PROPEL 52 ROCKET AF 52 MGd 52 oral Xeloda 52 eculizumab therapy 52 Phase 2b clinical trials 52 morphometric vertebral fractures 52 telaprevir dosing 52 Pazopanib 52 Ostarine 52 multicenter randomized clinical 52 secondary endpoint 52 BR.# 52 prospective multicenter randomized 52 CYPHER Stent 52 denosumab 52 huC# DM4 52 rosiglitazone 52 multicenter study 52 IMPACT IMmunotherapy 52 PROactive study 52 Hepatocellular Carcinoma HCC 52 CombAT 52 TBC# 52 NeuroFlo 52 TG MV 52 SCH # 52 ThermoDox R 52 betrixaban 52 INTELENCE 52 multicenter Phase III 52 gadobutrol 52 crizotinib PF # 52 talactoferrin 52 OvaRex MAb 52 Phase III randomized controlled 52 alogliptin 52 KRN# 52 YONDELIS 52 tecarfarin 52 eptifibatide 52 AEG# 52 ibandronate 52 bosutinib 52 decitabine 52 Qnexa 52 docetaxel Taxotere R 52 MBP# [001] 52 DAPT Study 52 Alzhemed TM 52 Mipomersen 52 ticagrelor 52 severe hypercholesterolemia 52 CLARITY study 52 Pirfenidone 52 candesartan 52 T DM1 52 atazanavir 52 JANUVIA 52 pharmacokinetics pharmacodynamics 52 EFAPROXYN 52 Traficet EN 52 lixisenatide 52 Clinical Antipsychotic Trials 52 subcutaneous PRO 52 cardiovascular morbidity 52 PRT# 52 cardio renal 52 DU #b 52 Sym# 52 Trovax 52 ONGLYZA 52 Tolamba 52 Insulin PH# 52 antibody MAb 52 #D#C# 52 midstage trials 52 Randomized Phase 52 iPrEx study 52 dose limiting toxicities 52 OHR/AVR# 52 febuxostat 52 Æterna Zentaris 52 Luveniq 52 DermaVir Patch 52 evaluating Actimmune 52 PRX # 52 Dr. Pingpank 52 HGS ETR2 52 methylnaltrexone 52 pralatrexate injection 52 LY# [003] 52 darunavir 52 mertansine 52 Octreolin 52 coadministration 52 Multicenter Automatic Defibrillator Implantation 52 reslizumab 52 LibiGel 52 NEVO ™ 52 CIMZIA ™ 52 CERVARIX 52 Ophthalmic Drugs Advisory 52 MAXY alpha 52 multicenter prospective 52 anti arrhythmic 52 olaparib 52 LCP AtorFen 52 Hedgehog Pathway Inhibitor 52 Proellex TM 52 favorable pharmacokinetic profile 52 pradefovir 52 tanespimycin 52 mipomersen 52 GnRH agonists 52 PEGylated interferon beta 1a 52 Bezielle 52 TAXUS ATLAS 52 Phase 2a clinical trials 52 CEQ# 52 Multiple Ascending Dose 52 CHARM Added 52 Cochrane reviewers 52 Phase IIb Trial 52 sipuleucel T 52 desvenlafaxine succinate 52 dosing intervals 52 Actilon 52 dacetuzumab 52 PANVAC VF 52 randomized controlled trials 52 Welchol 52 picoplatin 52 Subgroup analyzes 52 evaluating tivozanib 52 TASKi3 52 TIMI Study Group 52 Hematide 52 ORENCIA ® 52 Reverset 52 administered subcutaneously 52 teduglutide 52 metastatic HRPC 52 oral calcitonin 52 PEG PAL 52 Nexavar sorafenib 52 tapentadol ER 52 Tracleer R 52 NEO3 52 EmbraceAC 52 PROCRIT therapy 52 Telavancin 52 celgosivir 52 Levacor 52 TAXUS VI 52 bevacizumab 52 AASLD 52 Phase IIB clinical 52 Ixempra 52 ACCLAIM II 52 double blinded randomized 52 Randomized Evaluation 52 EVIZON 52 lasofoxifene 52 eliglustat tartrate 52 EDEMA4 52 European Sepsis Trial 52 Zoraxel 51 AVANDIA 51 Nuvion 51 cetuximab Erbitux 51 antiviral efficacy 51 TLK# 51 controlled multicenter 51 KOMBIGLYZE XR 51 IMPACT DCM 51 adalimumab 51 LymphoStat B 51 cediranib 51 Phase IIb Clinical Trial 51 Elitek 51 SPIRIT III 51 nitazoxanide 51 Edge STudy 51 TYGACIL 51 pharmacokinetic 51 PREOS 51 randomized double 51 Puricase 51 sorafenib Nexavar 51 fidaxomicin Phase 3 51 ofatumumab 51 fluvastatin 51 refractory CLL 51 double blind placebo 51 PCI ExTRACT TIMI 51 carboplatin paclitaxel 51 modified REGENESIS Phase IIb 51 FOLFOX4 51 Protelos 51 certolizumab pegol 51 Initiate Phase 51 varespladib 51 edoxaban 51 Troxatyl 51 PEG Interferon lambda 51 FOLFIRI 51 antiarrhythmic drug 51 Urocortin 2 51 PDX pralatrexate 51 midstage studies 51 Eugene Braunwald MD 51 etravirine 51 YERVOY 51 mg/m2 dose 51 Motesanib 51 TroVax 51 HAART regimens 51 prucalopride 51 liprotamase 51 RezularTM 51 perifosine 51 multicenter randomized Phase 51 meta analyzes 51 HCD# [002] 51 MyVax personalized immunotherapy 51 Perforomist TM Inhalation Solution 51 comparator arm 51 INSPIRE Trial Phase III 51 lipid lowering therapy 51 Novartis Zometa 51 randomized controlled multicenter 51 Virulizin R 51 dexpramipexole 51 OMAPRO 51 CYPHER ® Stent 51 CHARISMA trial 51 randomized multicenter Phase III 51 DLTs 51 urocortin 2 51 ARIXTRA 51 rALLy clinical trial 51 VA# [002] 51 Allovectin 7 51 Phase 2b randomized 51 limiting toxicity 51 lorvotuzumab mertansine 51 EGFR TKI 51 BYSTOLIC 51 safety tolerability pharmacokinetic 51 dosing regimens 51 BCX# 51 VIRAMUNE 51 LEXIVA 51 Primary endpoints 51 Ovarian PLCO Cancer 51 MelaFind pivotal 51 tramiprosate ALZHEMED TM 51 INCB# [003] 51 enoximone 51 IMPACT DCM clinical 51 intermittent dosing 51 National Surgical Adjuvant 51 Phase 1b dose escalation 51 II Clinical Trial 51 Pegloticase 51 ZACTIMA 51 Phase Ib IIa 51 Telcyta 51 sitagliptin 51 Afatinib 51 Phase III VISTA 51 CUSTOM II 51 Tyrima 51 Microplasmin 51 CBLC# 51 GRNVAC1 51 ACTOS 51 LPV r 51 Hedgehog antagonist 51 ORAL Sync 51 Fabry Disease 51 pralatrexate 51 IFN alfa 51 PROVENGE sipuleucel T 51 eltrombopag 51 Thrombolysis 51 tofacitinib 51 subcutaneously administered 51 Metabolic Drugs 51 randomized 51 LibiGel testosterone gel 51 Ambrisentan 51 pharmacodynamics 51 Diamyd R 51 Avastin bevacizumab 51 TOCOSOL Paclitaxel 51 phase III SIMPADICO 51 SYMBICORT 51 Entereg 51 CIMZIA TM certolizumab pegol 51 mg QD 51 docetaxel chemotherapy 51 pemetrexed 51 retrospective cohort 51 RG# [001] 51 achieved statistical significance 51 ICA # 51 SUTENT 51 TYKERB 51 almorexant 51 achieve statistical significance 51 BETAS 51 NCCTG 51 immunomodulatory therapy 51 trodusquemine 51 VAPRISOL 51 standard chemotherapy regimen 51 primary efficacy endpoint 51 ELACYT 51 metastatic castration resistant 51 SILENOR 51 #mg dosing group 51 urate lowering 51 relapsing MS 51 FOLOTYN 51 insulin detemir 51 pioglitazone 51 REMICADE ® 51 seliciclib 51 inhibitor RG# 51 trastuzumab DM1 T DM1 51 SYNTAX trial 51 Antiviral Activity 51 monotherapy 51 IIa trial 51 OvaRex ® MAb 51 trastuzumab DM1 51 dosing interval 51 melphalan prednisone 51 indacaterol 51 mcg kg 51 HORIZONS AMI 51 maraviroc 51 evaluating REVLIMID 51 anti leukemic 51 pharmacokinetic studies 51 bendamustine 51 NCCTG N# 51 MyVax 51 RRMS patients 51 dexanabinol 51 dual antiplatelet therapy 51 MMRV vaccine 51 ZYBRESTAT fosbretabulin 51 Phase III ALLEGRO 51 NSABP B 51 VPRIV 51 angiogenesis inhibitor 51 UVIDEM 51 ORBIT II 51 Pemetrexed 51 CAPRIE 51 sitaxsentan 51 tanezumab 51 Pre RELAX AHF 51 TMC# [001] 51 Long Term Efficacy 51 Randomized Phase II 51 Horizant 51 intravenous dosing 51 antiepileptic drug 51 postapproval 51 observational studies 51 ALVESCO HFA 51 atacicept 51 zanolimumab 51 STELARA 51 regorafenib 51 Imprime PGG 51 fondaparinux 51 REG2 51 Placebo Controlled Trial 51 NEUVENGE